Article

FDA OKs First Drug-Eluting Stents for Use in MI

Two drug-eluting stents from Boston Scientific have become the first to be approved by the FDA for treating patients with acute myocardial infarction (AMI), the company announced.

The paclitaxel-eluting Ion and Taxus Liberté stents gained approval for AMI primarily on the strength of the evidence from the HORIZONS-AMI trial.

HORIZONS-AMI randomized 3,006 patients to bare-metal or Taxus stents. At three years, there were no significant differences in safety, including all-cause death, reinfarction, stent thrombosis, or stroke.

Read the full story: http://hcp.lv/yWMJQg

Source: MedPage Today

Related Videos
Lawrence Eichenfield, MD, FAAD
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Michelle Hessen, OD
Douglas Flora, MD, FACCC
Molly Dean, MSW, Siftwell
Dr Xin Hu
Bridgette J. Picou, LVN, ACLPN, The Well Project
Priscilla Tsondai, MD, MPH, IAS/CIPHER
Mia Moore, PhD, Fred Hutch Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo